62
Participants
Start Date
September 15, 2020
Primary Completion Date
July 27, 2023
Study Completion Date
February 9, 2024
dupilumab
Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
Placebo
Matching placebo
Regeneron Study Site, Budapest
Regeneron Study Site, Sofia
Regeneron Study Site, Leipzig
Regeneron Study Site, Smolyan
Regeneron Study Site, Eindhoven
Regeneron Study Site, Haskovo
Regeneron Study Site, Arnhem
Regeneron Study Site, Razgrad
Regeneron Study Site, Zutphen
Regeneron Study Site, New York
Regeneron Study Site, The Bronx
Regeneron Study Site, Berlin
Regeneron Study Site, Marseille
Regeneron Study Site, DuBois
Regeneron Study Site, Philadelphia
Regeneron Study Site, Brest
Regeneron Study Site, Montpellier
Regeneron Study Site, Rennes
Regeneron Study Site, Birmingham
Regeneron Study Site, Tours
Regeneron Study Site, Columbus
Regeneron Study Site, Iowa City
Regeneron Study Site, Frankfurt am Main
Regeneron Study Site, Lyon
Regeneron Study Site, Paris
Regeneron Study Site, Gdansk
Regeneron Study Site, Boise
Regeneron Study Site, Scottsdale
Regeneron Study Site, Los Angeles
Regeneron Study Site, La Jolla
Regeneron Study Site, Riverside
Regeneron Study Site, Bakersfield
Regeneron Study Site, Oradea
Regeneron Study Site, Brasov
Regeneron Study Site, Naka-gun
Regeneron Study Site, Fukuyama
Regeneron Study Site, Yanagawa
Regeneron Study Site, Kanagawa
Regeneron Study Site, Nagoya
Regeneron Study Site, Sakai
Regeneron Study Site, Yokohama
Regeneron Study Site, Amsterdam
Regeneron Study Site, Breda
Regeneron Study Site, Bialystok
Regeneron Study Site, Leicester
Regeneron Study Site, Liverpool
Regeneron Study Site, London
Regeneron Study Site, London
Regeneron Study Site, Wythenshawe
Regeneron Study Site, Bradford
Collaborators (1)
Sanofi
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY